SCYNEXIS, Inc. announced on April 8, 2025, that it would present preclinical efficacy data on its second-generation fungerp candidate, SCY-247, at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global). The conference is scheduled to take place in Vienna, Austria, from April 11-15, 2025.
SCY-247 is being developed to address the significant threat posed by antimicrobial resistance in systemic fungal diseases. The presentation of preclinical data at this international forum underscores the compound's potential.
This continued sharing of positive preclinical data for SCY-247 reinforces its promise as a novel therapeutic. It highlights SCYNEXIS's ongoing commitment to developing innovative solutions for difficult-to-treat infections.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.